{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling in tumor tissue",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "Type I interferon response score (normalized units) 3.1 vs 1.0 baseline",
          "line_ref": "L31"
        }
      ],
      "caveat": "The interferon response was measured at the protein and transcript level, but the downstream effects varied across different tumor models"
    },
    {
      "claim_id": "C02",
      "claim": "Interferon-associated antigen processing and presentation pathways are upregulated following mRNA vaccination",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Interferon-associated antigen processing and presentation pathways increase.",
          "line_ref": "L43"
        },
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome 62.3% vs 37.3% baseline",
          "line_ref": "L28"
        }
      ],
      "caveat": "The expansion of antigen presentation was demonstrated through immunopeptidomics but the functional consequences for T-cell recognition require additional validation"
    },
    {
      "claim_id": "C03",
      "claim": "A broader peptide repertoire appears on MHC-I molecules after mRNA vaccination, improving tumor visibility to T cells",
      "strength": "strong",
      "evidence": [
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        },
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome 40.6% vs 20.6% baseline",
          "line_ref": "L29"
        }
      ],
      "caveat": "While the peptide repertoire expanded significantly, the direct link to improved T-cell recognition was inferred from in vivo tumor control rather than direct T-cell assays"
    },
    {
      "claim_id": "C04",
      "claim": "PD-L1 pathway activity increases following mRNA vaccination, creating a rationale for combining with checkpoint blockade",
      "strength": "strong",
      "evidence": [
        {
          "quote": "PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.",
          "line_ref": "L45"
        },
        {
          "quote": "PD-L1 expression fold-change in tumor tissue 2.4x vs 1.0x baseline",
          "line_ref": "L32"
        }
      ],
      "caveat": "PD-L1 expression increased at the protein level, but the relationship between expression and actual checkpoint activity was not directly measured in this study"
    },
    {
      "claim_id": "C05",
      "claim": "Combined intratumoral mRNA vaccination and anti-PD-L1 therapy improves tumor control in mice",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        },
        {
          "quote": "Intratumoral CD8+ T-cell density fold-change 1.8x vs 1.0x baseline",
          "line_ref": "L33"
        }
      ],
      "caveat": "Efficacy was demonstrated in multiple murine tumor models, but the effect size varied and was strongest in more immunogenic tumor types"
    },
    {
      "claim_id": "C06",
      "claim": "Prior SARS-CoV-2 mRNA vaccination is associated with improved survival in metastatic cancer patients receiving ICI treatment",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "Retrospective human survival comparison p-value p=0.01",
          "line_ref": "L30"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; vaccination timing varied and residual confounding cannot be ruled out"
    }
  ]
}